CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
Key Highlights
- ➤$984.5 million cash, equivalents and securities funds operations through 2029
- ➤PIVOT-006 Phase 3 topline data anticipated November 2026
- ➤BOND-003 Cohort P 12-month data anticipated December 2026
- ➤CORE-008 Cohort CX 12-month data anticipated December 2026
- ➤Net loss widened to $56.9 million from $43.8 million year over year
Expert Statements
Arthur Kuan, Chairman, President and Chief Executive Officer at CG Oncology
“We are entering an eventful period for CG Oncology as we look forward to sharing PIVOT-006 topline data this month. As a reminder, PIVOT-006 is the first randomized registrational trial in intermediate-risk and high-grade Ta NMIBC. Additionally, we expect to have 12-month data from both CORE-008 Cohort CX and BOND-003 Cohort P in December, which further strengthens the growing body of evidence for cretostimogene across the NMIBC landscape and supports our goal to address the broadest number of patients. We remain confident in cretostimogene’s potential to become a backbone therapy for patients and to create long-term value for shareholders”
* PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026 * BOND-003 Cohort P and CORE-008 Cohort CX 12-month data anticipated December 2026 * BLA completion for BCG-unresponsive NMIBC anticipated Q4 2026 * Well-positioned to deliver on key milestones with approximately $984.5 million of cash, cash equivalents and marketable securities sufficient to fund operations through 2029 DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September 30, 2026, and provided business updates.
“We are entering an eventful period for CG Oncology as we look forward to sharing PIVOT-006 topline data this month. As a reminder, PIVOT-006 is the first randomized registrational trial in intermediate-risk and high-grade Ta NMIBC. Additionally, we expect to have 12-month data from both CORE-008 Cohort CX and BOND-003 Cohort P in December, which further strengthens the growing body of evidence for cretostimogene across the NMIBC landscape and supports our goal to address the broadest number of patients. We remain confident in cretostimogene’s potential to become a backbone therapy for patients and to create long-term value for shareholders,” stated Arthur Kuan, Chairman, President & Chief Executive Officer at CG Oncology.
Get started
Create a free account to read the full story.